Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice

References

• GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)Chest20081336 Suppl381S453S18574271
   PubMed Web of Science ®Google Scholar
• HamidiVRingerikeTHagenGReikvamAKlempMNew anticoagulants as thromboprophylaxis after total hip or knee replacementInt J Technol Assess Health Care201329323424323768996
   PubMed Web of Science ®Google Scholar
• FriedmanRJNew oral anticoagulants for thromboprophylaxis after total hip or knee arthroplastyOrthopedics20093212 Suppl798420201481
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med2008358262765277518579811
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet20083729632313918582928
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med2008358262776278618579812
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRDavidsonBLRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet200937396761673168019411100
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRErikssonBIRivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studiesThromb Haemost2011105344445321136019
   PubMed Web of Science ®Google Scholar
• LassenMRGentMKakkarAKThe effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programmeJ Bone Joint Surg Br201294111573157823109641
   PubMedGoogle Scholar
• FroschPDeckingJTheisCDreesPSchoellnerCEckardtAComplications after total knee arthroplasty: a comprehensive reportActa Orthop Belg200470656556915669457
   PubMedGoogle Scholar
• TurpieAGHaasSKreutzRA non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustmentThromb Haemost201411119410224154549
   PubMed Web of Science ®Google Scholar
• JensenCDStevalAPartingtonPFReedMRMullerSDReturn to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort studyJ Bone Joint Surg Br2011931919521196550
   PubMedGoogle Scholar
• JamesonSSRymaszewskaMJamesPWound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplastyJ Bone Joint Surg Am201294171554155822832942
   PubMed Web of Science ®Google Scholar
• ChahalGSaithnaABrewsterMA comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxisOrtop Traumatol Rehabil201315212513023652532
   PubMedGoogle Scholar
• European Medicines AgencyGuideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127902.pdfAccessed January 20, 2016
   Google Scholar
• Beyer-WestendorfJLütznerJDonathLEfficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registryJ Thromb Haemost201210102045205222882706
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJLütznerJDonathLEfficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registryThromb Haemost2013109115416323197272
   PubMed Web of Science ®Google Scholar
• Lazo-LangnerAFleetJLMcArthurEGargAXRivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort studyJ Thromb Haemost201412101626163525069387
   PubMed Web of Science ®Google Scholar
• SindaliKRoseBSoueidHJeerPSaranDShrivastavaRElective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healingEur J Orthop Surg Traumatol201323448148623412293
   PubMedGoogle Scholar
• HeckmannMHillebrandISilayHRivaroxaban superior to nadroparin for thromboprophylaxis in patients receiving hip or knee arthroplastyJ Thromb Haemost201311Suppl 3PB3466
   Google Scholar
• MonzonDGIsersonKVCidAVazquezJAOral thromboprophylaxis in pelvic trauma: a standardized protocolJ Emerg Med201243461261722244290
   PubMed Web of Science ®Google Scholar
• ClavéAFazilleauFDumserDLacroixJEfficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patientsOrthop Traumatol Surg Res2012125484490
   Web of Science ®Google Scholar
• NiskanenROKorkalaOLTranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritisActa Orthop200576682983216470437
   PubMed Web of Science ®Google Scholar
• RajesparanKBiantLCAhmadMFieldREThe effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacementJ Bone Joint Surg Br200991677678319483232
   PubMedGoogle Scholar
• Beyer-WestendorfJFörsterKPannachSRates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC RegistryBlood2014124695596224859362
   PubMed Web of Science ®Google Scholar
• LinkinsLAChoiPTDouketisJDClinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysisAnn Intern Med20031391189390014644891
   PubMed Web of Science ®Google Scholar
• GomesTMamdaniMMHolbrookAMPatersonJMHellingsCJuurlinkDNRates of hemorrhage during warfarin therapy for atrial fibrillationCMAJ20131852E121E12723184840
   PubMed Web of Science ®Google Scholar
• WeberJCEpidemiology of adverse reactions to nonsteroidal antiin-flammatory drugsRainsfordKDVeloGPAdvances in Inflammatory ResearchNew YorkRaven Press198417
   Google Scholar
• YenSHLinPCKuoFCWangJWThromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparinBiomed J201437419920425116715
   PubMedGoogle Scholar
• RathNKThe use of rivaroxaban for chemical thromboprophylaxis following total knee replacementKnee201320639740023566737
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJOral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgeryDrugs200666111411142916906775
   PubMed Web of Science ®Google Scholar
• TurpieABauerKErikssonBLassenMEfficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administrationThromb Haemost200390236436612888887
   PubMed Web of Science ®Google Scholar
• HaasSRivaroxaban or standard thromboprophylaxis in routine clinical practice: outcomes by time to anticoagulant initiation in the XAMOS studyOral presentation at: European Federation of National Associations of Orthopaedics and Traumatology 2014 Annual MeetingJune 4–6, 2014London, UK Available from: http://efort.conference2web.com/content/3479/details?from_view=all&view_address=search%3Dhaas%26events%3D3Accessed July 27, 2016
   Google Scholar
• Bayer PharmaAGXarelto (rivaroxaban) [summary of product characteristics]2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed March 21, 2016
   Google Scholar
• RosencherNBonnetMPSesslerDISelected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategiesAnaesthesia200762111154116017924897
   PubMed Web of Science ®Google Scholar
• HaasSHolbergGKreutzRLassenMRMantovaniLTurpieAGRivaroxaban or conventional thromboprophylaxis in routine clinical care: subgroup analysis of the XAMOS study by types of anesthesia usedAbstract A 100 presented at: ASRA 38th Annual Regional Anesthesia and Acute Pain Medicine MeetingMay 2–5 2013Boston, MA
   Google Scholar
• RosencherNLlauJVMueckWLoeweABerkowitzSDHomeringMIncidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin)Acta Anaesthesiol Scand201357556557223336294
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMMueckWEffects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitorBr J Clin Pharmacol201070570371221039764
   PubMed Web of Science ®Google Scholar
• Beyer-WestendorfJGelbrichtVForsterKPeri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registryEur Heart J201435281888189624394381
   PubMed Web of Science ®Google Scholar
• TurpieAGKreutzRLlauJNorrvingBHaasSManagement consensus guidance for the use of rivaroxaban – an oral, direct Factor Xa inhibitorThromb Haemost2012108587688623014816
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace201315562565123625942
   PubMed Web of Science ®Google Scholar
• OsterGTudenRLColditzGAA cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgeryJAMA198725722032083098991
   PubMed Web of Science ®Google Scholar
• KwongLMDuranADiamantopoulosASenguptaNLeesMCost-effectiveness of rivaroxaban for prevention of venous thromboembolism (VTE) after total hip or knee replacement (THR, TKR) in the USJ Thromb Haemost20097Suppl 278719320828
   PubMed Web of Science ®Google Scholar
• FriedmanRJSenguptaNLeesMEconomic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxabanExpert Rev Pharmacoecon Outcomes Res201111329930621671699
   PubMed Web of Science ®Google Scholar
• LongAZhangLZhangYEfficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fracturesJ Thromb Thrombolysis2014383229305
   Web of Science ®Google Scholar
• McNamaraISharmaAPrevostTParkerMSymptomatic venous thromboembolism following a hip fractureActa Orthop200980668769219968601
   PubMed Web of Science ®Google Scholar
• Falck-YtterYFrancisCWJohansonNAPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed – American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Supple278Se325S22315265
   PubMed Web of Science ®Google Scholar
• ErikssonBIBauerKALassenMRTurpieAGFondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgeryN Engl J Med2001345181298130411794148
   PubMed Web of Science ®Google Scholar
• LassenMRHaasSKreutzRMantovaniLGHolbergGTurpieAGRivaroxaban for thromboprophylaxis after fracture-related orthopedic surgery in routine clinical practiceClin Appl Thromb Hemost201622213814626408640
   PubMed Web of Science ®Google Scholar
• MuñoaLGonzálezABDíaz de RadaPValentíAValentíJRRivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopyMusculoskelet Surg2014981212523852662
   PubMedGoogle Scholar